StreetTalk: Will Venture Capital Firms Turn Their Backs on Stem-Cell Research? - Korea-gate has proven to be a huge scandal, not only in science, but in finance, where investors who thought Suk was

ADVERTISEMENT

StreetTalk: Will Venture Capital Firms Turn Their Backs on Stem-Cell Research?
Korea-gate has proven to be a huge scandal, not only in science, but in finance, where investors who thought Suk was on to something potentially significant in stem-cell research, were left with empty promises . . .


BioPharm International
Volume 19, Issue 2

Now, in an environment clouded by the Korean stem-cell scandal, how will a company that just saw its stock share value decrease by 66% manage to convince venture capitalists to fork over more money?

It won't be easy. While it's true that the federal government is usually the prime financial contributor to emerging medical technologies, the stem-cell environment still has an uphill battle.

With the scandal in Korea and a lack of quantifiable research available, venture capitalists are understandably skittish.

I doubt that's going to change anytime soon.

Celebrity author and business/finance commentator for CNN and Fox News, Brian O'Connell has written for The Wall Street Journal and Newsweek, 79 Radcliffe Drive,Doylestown, PA 18901, 267.880.3144, fax 267.880.1939


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here